Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018

Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.

Money Wave

South Korea is set for a robust year of initial public offerings (IPOs) by biotech and pharma companies following a substantial rally in the sector last year and the government’s recent move to ease listing requirements for the Kosdaq share market.

Although there aren’t likely to be sizable offerings like that by Celltrion Healthcare launched last year, the number of floats...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip